United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori Infection

Core Viewpoint - Biomerica, Inc. has received regulatory approval for its Fortel Ulcer Test in the UAE, enabling the introduction of a rapid diagnostic tool for Helicobacter pylori infection, addressing a significant public health concern in the region [1][5]. Group 1: Product Overview - The Fortel Ulcer Test is a quick and user-friendly diagnostic tool that detects antibodies to H. pylori, providing accurate results in just 10 minutes [2][8]. - H. pylori infection is linked to various gastrointestinal diseases, including peptic ulcers, dyspepsia, and gastric cancer, with approximately 80% of gastric cancer cases attributed to this bacterium [4][8]. Group 2: Market Context - H. pylori infects about 35% of the U.S. population and 45% in the five largest European countries, with local studies in the UAE estimating infection rates exceeding 50% [3]. - The World Health Organization has classified H. pylori as a Class 1 carcinogen and identified it as one of the top 16 antibiotic-resistant bacteria posing a significant health threat [4]. Group 3: Strategic Impact - The approval of the Fortel Ulcer Test enhances Biomerica's presence in the Middle East, following the successful launch of other diagnostic products [5]. - The company is collaborating with local distributors and healthcare providers to ensure the availability of the Fortel Ulcer Test throughout the UAE [5][6]. Group 4: Company Mission - Biomerica is focused on delivering affordable and innovative diagnostic tools aimed at improving patient outcomes through early disease detection [6][7]. - The Fortel Ulcer Test aligns with the company's mission to enhance global health by providing fast and accessible diagnostics [6].